Obinutuzumab (Gazyva ®)
Obinutuzumab is an immunotherapy medicine used in the treatment of CLL with a promising outlook in treatment for other subtypes of lymphoma in the future. Obinutuzumab works by binding to a protein on the surface of certain white cells known as B lymphocytes and by bonding to this protein the abnormal growth in the B lymphocyte is stopped therefore decreasing the number of CLL cells in the body.
Once attached to the CD20 protein Obinutuzumab helps the immune system destroy the CLL cells and also destroys the CLL cells on its own by directly killing them. Obinutuzumab is the only monoclonal antibody with proven superiority to rituximab for the treatment for CLL when used in combination with chlorambucil as proven in clinical trials.
Obinutuzumab is given by intravenous infusion which means it goes directly into the vein through a needle in your arm or through a central line if you have one in place.
Obinutuzumab is given every week for 3 weeks then once every four weeks in combination with chlorambucil depending on your subtype of lymphoma.
Obinutuzumab may have the following side effects:
• Hair loss
• Lowered blood counts
• Mouth sores
• Skin problems
Refer to the (obinutuzumab) Consumer Medicines Information for more side effects.
Obinutuzumab is approved by the TGA and listed on the PBS for the following indications:
• CLL as a first line treatment in combination with chlorambucil
"If my lymphoma relapses I hope I can have access to the best available treatment for me"